-

Global Cancer Anorexia-Cachexia Syndrome Disease Clinical Trials Review, H2 2020 Edition Featuring 10 Key Players & Their Respective Trials - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cancer Anorexia-Cachexia Syndrome Disease - Global Clinical Trials Review, H2, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

"Cancer Anorexia-Cachexia Syndrome Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Cancer Anorexia-Cachexia Syndrome Clinical trials scenario.

This report provides top line data relating to the clinical trials on Cancer Anorexia-Cachexia Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

Report Guidance

  • Clinical Trials Report Coverage

Clinical Trials by Region

  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Cancer Anorexia-Cachexia Syndrome to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Cancer Anorexia-Cachexia Syndrome to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

  • In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

  • Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

  • Prominent Sponsors

Top Companies Participating in Cancer Anorexia-Cachexia Syndrome Therapeutics Clinical Trials

Prominent Drugs

  • Clinical Trial Profile Snapshots

Appendix

Companies Mentioned

  • Helsinn Group
  • Oncternal Therapeutics
  • Aeterna Zentaris Inc
  • Pfizer Inc
  • Ono Pharmaceutical Co Ltd
  • Ark Therapeutics Ltd
  • AstraZeneca Plc
  • Endo International Plc
  • IQVIA Holdings Inc
  • Medpace Holdings Inc

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/mryc8a

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Malaysia Defense Industry Report 2025: $4.8 Billion Allocation in 2025 Reflects 6.0% CAGR Growth Momentum - Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Malaysia Defense Market - Size and Trends, Budget Allocation, Regulations, Key Acquisitions, Competitive Landscape and Forecast, 2025-2030" report has been added to ResearchAndMarkets.com's offering. The report provides the market size forecast and the projected growth rate for the next five years. The report covers industry analysis including the key market drivers, emerging technology trends, and major challenges faced by market participants. It also offers insig...

France Defense Industry Report 2025: Defense Expenditure Driven by Domestic Modernization Programs, Russia and the Invasion of Ukraine and NATO Alliance - Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "France Defense Market - Size and trends, budget allocation, regulations, key acquisitions, competitive landscape and forecast, 2025-2030" report has been added to ResearchAndMarkets.com's offering. The report provides the market size forecast and the projected growth rate for the next five years. The report covers industry analysis including the key market drivers, emerging technology trends, and major challenges faced by market participants. It also offers insight...

$43.4 Bn Orphan Drugs Service Markets 2019-2024, 2024-2029F, 2034F - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs Service Market Report 2025" has been added to ResearchAndMarkets.com's offering. The global orphan drugs service market is witnessing unprecedented growth, reflecting the increasing focus on rare diseases, investment in biopharmaceutical research, and enhanced collaborations between healthcare providers and researchers. From $37.05 billion in 2024, the market is projected to soar to $43.4 billion by 2025, with a robust CAGR of 17.1%. Growth drivers inc...
Back to Newsroom